Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice
Phase of Trial: Phase IV
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Roche
- 01 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Nov 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 02 Nov 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.